Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of interleukin-2 injected perilymphatically.

Authors: Cortesina, G  De Stefani, A  Giovarelli, M  Barioglio, MG  Cavallo, GP  Jemma, C  Forni, G 
Citation: Cortesina G, etal., Cancer. 1988 Dec 15;62(12):2482-5.
Pubmed: (View Article at PubMed) PMID:3263896

Ten patients with recurrent squamous cell carcinoma of the head and neck received daily injections of interleukin-2 (IL-2) from the Jurkat T-cell line purified by high pressure liquid chromatography for 10 days. Two hundred units of IL-2 in 0.5 ml were injected 1.5 cm from the insertion of the sternocleidomastoid muscle on the mastoid. When possible, courses were repeated at 45-day intervals. IL-2 was ineffective in two patients who had already undergone functional or radical neck dissection. By contrast, in six patients with contralateral or bilateral cervical lymph nodes, complete or partial disappearance of the tumor was observed. The injections were occasionally followed by moderate local swelling and lymph node pain, but no systemic disturbances.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 8662923
Created: 2014-06-27
Species: All species
Last Modified: 2014-06-27
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.